Carcinoid-syndrome: recent advances, current status and controversies. Issue 1 (February 2018)

• Record Type: Journal Article
• Authors: Ito, Tetsuhide; Lee, Lingaku; Jensen, Robert T.
• Is Part Of: Current opinion in endocrinology, diabetes and obesity. Volume 25:Issue 1(2018:Feb.)
• Publication Date: 2018-02
• Subjects: carcinoid-syndrome -- neuroendocrine tumor -- peptide radioreceptor therapy -- somatostatin -- telotristat; Endocrinology -- Periodicals; Diabetes -- Periodicals; Obesity -- Periodicals; Diabetes Mellitus -- Periodicals; Endocrine System Diseases -- Periodicals; Endocrine Glands -- Periodicals; Obesity -- Periodicals; Endocrinologie -- Périodiques; Diabète -- Périodiques; Obésité -- Périodiques; Diabetes; Endocrinology; Obesity; Periodicals; 616.4
• DOI: 10.1097/MED.0000000000000376
• Languages: English
• ISSNs: 1752-296X

Abstract

Abstract : Purpose of review: To review recent advances and controversies in all aspects of carcinoid-syndrome. Recent findings: Over the last few years there have been a number of advances in all aspects of carcinoid syndrome as well as new therapies. These include new studies on its epidemiology which demonstrate it is increasing in frequency; increasing insights into the pathogenesis of its various clinical manifestations and into its natural history: definition of prognostic factors; new methods to verify its presence; the development of new drugs to treat its various manifestations, both initially and in somatostatin-refractory cases; and an increased understanding of the pathogenesis, natural history and management of carcinoid heart disease. These advances have generated several controversies and these are also reviewed. Summary: There have been numerous advances in all aspects of the carcinoid-syndrome, which is the most common functional syndrome neuroendocrine tumors produce. These advances are leading to new approaches to the management of these patients and in some cases to new controversies.